165 related articles for article (PubMed ID: 28005492)
1. Feline Injection-Site Sarcoma.
Porcellato I; Menchetti L; Brachelente C; Sforna M; Reginato A; Lepri E; Mechelli L
Vet Pathol; 2017 Mar; 54(2):204-211. PubMed ID: 28005492
[TBL] [Abstract][Full Text] [Related]
2. Feline eosinophilic dermatoses: a retrospective immunohistochemical and ultrastructural study of extracellular matrix remodelling.
Porcellato I; Giontella A; Mechelli L; Del Rossi E; Brachelente C
Vet Dermatol; 2014 Apr; 25(2):86-94, e26. PubMed ID: 24666659
[TBL] [Abstract][Full Text] [Related]
3. DNA damage is a feature of feline injection-site sarcoma.
Kang S; Southard T; Hume KR
Vet Comp Oncol; 2017 Jun; 15(2):518-524. PubMed ID: 26781433
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological and morphological analysis of feline injection site sarcomas.
Kliczkowska K; Jankowska U; Jagielski D; Czopowicz M; Sapierzyński R
Pol J Vet Sci; 2015; 18(2):313-22. PubMed ID: 26172181
[TBL] [Abstract][Full Text] [Related]
5. CT angiography and MRI imaging features do not predict the tumor type and grade of feline injection site sarcoma.
Fleming K; Nemanic S; Löhr CV; Terry J; Milovancev M
Vet Radiol Ultrasound; 2019 Nov; 60(6):668-679. PubMed ID: 31515897
[TBL] [Abstract][Full Text] [Related]
6. Lack of association between p53 SNP and FISS in a cat population from Germany.
Mucha D; Laberke S; Meyer S; Hirschberger J
Vet Comp Oncol; 2014 Jun; 12(2):130-7. PubMed ID: 22882519
[TBL] [Abstract][Full Text] [Related]
7. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant and adjuvant chemotherapy combined with anatomical resection of feline injection-site sarcoma: results in 21 cats.
Bray J; Polton G
Vet Comp Oncol; 2016 Jun; 14(2):147-60. PubMed ID: 24502401
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
10. Expression and localization of matrix metalloproteinases (MMP-2, -7, -9) and their tissue inhibitors (TIMP-2, -3) in the chicken oviduct during pause in laying induced by tamoxifen.
Leśniak-Walentyn A; Hrabia A
Theriogenology; 2017 Jan; 88():50-60. PubMed ID: 27865412
[TBL] [Abstract][Full Text] [Related]
11. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
[TBL] [Abstract][Full Text] [Related]
12. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptor expression, clinical and histopathological analysis in feline injection site sarcomas.
Zanuncio VV; Conceição LG; Loures FH; Cassali GD; Rocha K; Lima BM
Vet Comp Oncol; 2021 Sep; 19(3):473-481. PubMed ID: 33211351
[TBL] [Abstract][Full Text] [Related]
14. Recurrent and non-recurrent feline injection-site sarcoma: computed tomographic and ultrasonographic findings.
Zardo KM; Damiani LP; Matera JM; Fonseca-Pinto AC
J Feline Med Surg; 2016 Oct; 18(10):773-82. PubMed ID: 26208864
[TBL] [Abstract][Full Text] [Related]
15. Role of nuclear factor-kappa B in feline injection site sarcoma.
Hsueh CS; Wu CH; Shih CH; Yeh JL; Jeng CR; Pang VF; Chiou HY; Chang HW
BMC Vet Res; 2019 Oct; 15(1):365. PubMed ID: 31653220
[TBL] [Abstract][Full Text] [Related]
16. Radical excision with five-centimeter margins for treatment of feline injection-site sarcomas: 91 cases (1998-2002).
Phelps HA; Kuntz CA; Milner RJ; Powers BE; Bacon NJ
J Am Vet Med Assoc; 2011 Jul; 239(1):97-106. PubMed ID: 21718202
[TBL] [Abstract][Full Text] [Related]
17. Expression of the metalloproteases MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, TIMP-1 and TIMP-2 in angiocentric midfacial lymphomas.
Meneses-García A; Betancourt AM; Abarca JH; Montes AB; Roa LS; Ruíz-Godoy L
World J Surg Oncol; 2008 Oct; 6():114. PubMed ID: 18954439
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Expression Profiles of Cell Adhesion Molecules, Matrix Metalloproteinases and their Tissue Inhibitors in Central and Peripheral Neoplastic Foci of Feline Mammary Carcinoma.
Pisamai S; Rungsipipat A; Kunnasut N; Suriyaphol G
J Comp Pathol; 2017; 157(2-3):150-162. PubMed ID: 28942298
[TBL] [Abstract][Full Text] [Related]
19. Elucidating the transcriptional program of feline injection-site sarcoma using a cross-species mRNA-sequencing approach.
Wei Q; Ramsey SA; Larson MK; Berlow NE; Ochola D; Shiprack C; Kashyap A; Séguin B; Keller C; Löhr CV
BMC Cancer; 2019 Apr; 19(1):311. PubMed ID: 30947707
[TBL] [Abstract][Full Text] [Related]
20. Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by Porphyromonas gingivalis in an engineered human oral mucosa model.
Andrian E; Mostefaoui Y; Rouabhia M; Grenier D
J Cell Physiol; 2007 Apr; 211(1):56-62. PubMed ID: 17226791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
